CBT-004 is a novel, preservative-free ophthalmic solution targeting VEGF and PDGF receptors to treat vascularized pinguecula. Phase 2 trial results showed significant improvements in conjunctival ...
Credit: Alcon. The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors. Tryptyr significantly improved tear production compared with ...
(RTTNews) - Glenmark Pharmaceuticals Ltd. (GLENMARK.NS), Friday announced that it has introduced Latanoprost Ophthalmic Solution, 0.005 percent, a bioequivalent and therapeutically equivalent ...
NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that VEVYE® (cyclosporine ophthalmic solution) 0.1%, a patented, non‑preserved, ...
BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company ...
Dexamethasone sodium phosphate 0.1%; oph soln; contains benzalkonium chloride. Initial therapy: 1 or 2 drops in conjunctival sac every hour during the day and every two hours during the night. When ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Phentolamine mesylate ophthalmic solution improved ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. IOP decreased with the use of VVN539 in a phase 2 study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results